Shares rise on stem cell study
Shares of Geron Corp. jumped Tuesday after the company said it began a clinical trial of embryonic stem cell treatment for injuries of the spinal cord.
SPARK: On Monday, the company said it received its first patient in phase 1 or early-stage study. The study aims to test the safety and tolerability not only the efficiency.
THE BIG PICTURE: Embryonic stem cells, which are derived from embryos, have the capacity to become any cell type. This study, which was expected, marks the first study approved by the Food and Drug Administration of an embryonic stem cell therapy.
ANALYSIS: Rodman & Renshaw analyst Reni Benjamin reaffirmed a “market outperform” rating and a price target of $ 9 in the population. He said the registration of a patient in the study “represents a landmark transformation of Geron.”
SOCIAL ACTION: up 33 cents, or 5.8 percent, to $ 6 in morning trading Tuesday. The stock has traded between $ 4.37 and $ 7.18 in the last 52 weeks.